Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer

NCT02424617 is registered in ClinicalTrials.gov with BerGenBio ASA as lead sponsor.

NCT NCT02424617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02424617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Lead sponsor
BerGenBio ASA
Phase
Phase 1/2
Overall status
Completed
Start date
April 19, 2015
Completion date
August 25, 2021
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer